Zoetis (NYSE:ZTS) Trading Down 0.4%

Zoetis Inc. (NYSE:ZTS)’s share price traded down 0.4% during mid-day trading on Monday . The stock traded as low as $145.97 and last traded at $145.97. 964,659 shares were traded during trading, a decline of 68% from the average session volume of 3,003,641 shares. The stock had previously closed at $146.50.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. The Goldman Sachs Group increased their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $218.00.

Zoetis Stock Up 2.8 %

The stock has a market capitalization of $68.40 billion, a PE ratio of 29.50, a price-to-earnings-growth ratio of 2.22 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The company’s 50-day moving average is $173.78 and its 200 day moving average is $179.78.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 earnings per share. As a group, analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 34.12%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.15% of the stock is owned by insiders.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently bought and sold shares of ZTS. Blue Bell Private Wealth Management LLC grew its stake in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky grew its stake in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Private Wealth Management Group LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $33,000. Webster Bank N. A. grew its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the period. Finally, Moisand Fitzgerald Tamayo LLC grew its stake in shares of Zoetis by 105.5% during the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.